

Title (en)
PREPARATION COMPRISING ANTI-PD-1/HER2 BISPECIFIC ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Title (de)
PRÄPARAT MIT ANTI-PD-1/HER2-BISPEZIFISCHEM ANTIKÖRPER SOWIE VERFAHREN ZU SEINER HERSTELLUNG UND VERWENDUNG DAVON

Title (fr)
PRÉPARATION COMPRENANT UN ANTICORPS BISPÉCIFIQUE ANTI-PD 1/HER2, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION

Publication
EP 4011390 A4 20230913 (EN)

Application
EP 20849224 A 20200806

Priority
• CN 201910726334 A 20190807
• CN 2020107441 W 20200806

Abstract (en)
[origin: EP4011390A1] The present invention relates to formulations comprising an anti-PD-1/HER2 bispecific antibody, and in particular to a pharmaceutical formulation comprising the anti-PD-1/HER2 bispecific antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations.

IPC 8 full level
A61K 39/395 (2006.01); **A61K 9/08** (2006.01)

CPC (source: EP KR US)
A61K 9/0019 (2013.01 - EP KR US); **A61K 9/08** (2013.01 - EP KR); **A61K 39/39591** (2013.01 - KR); **A61K 47/10** (2013.01 - KR); **A61K 47/22** (2013.01 - KR); **A61K 47/26** (2013.01 - KR US); **A61P 35/00** (2018.01 - EP KR US); **C07K 16/2803** (2013.01 - US); **C07K 16/2818** (2013.01 - EP KR); **C07K 16/32** (2013.01 - EP KR); **A61K 47/10** (2013.01 - EP); **A61K 47/22** (2013.01 - EP); **A61K 47/26** (2013.01 - EP); **A61K 2039/505** (2013.01 - KR US); **C07K 2317/31** (2013.01 - EP KR); **C07K 2317/52** (2013.01 - EP); **C07K 2317/56** (2013.01 - EP); **C07K 2317/565** (2013.01 - EP); **C07K 2317/64** (2013.01 - EP); **C07K 2317/94** (2013.01 - EP)

Citation (search report)
• [I] WO 2018090950 A1 20180524 - BEIJING HANMI PHARMACEUTICAL CO LTD [CN]
• [I] VIOLA MARGARIDA ET AL: "Subcutaneous delivery of monoclonal antibodies: How do we get there?", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 286, 2 August 2018 (2018-08-02), pages 301 - 314, XP085478006, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2018.08.001
• [I] NEAL WHITAKER ET AL: "A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 106, no. 11, 1 November 2017 (2017-11-01), US, pages 3230 - 3241, XP055449627, ISSN: 0022-3549, DOI: 10.1016/j.xphs.2017.06.017
• [I] UCHIYAMA SUSUMU ED - SHUGAR DAVID ET AL: "Liquid formulation for antibody drugs", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, NETHERLANDS, vol. 1844, no. 11, 13 August 2014 (2014-08-13), pages 2041 - 2052, XP029050319, ISSN: 1570-9639, DOI: 10.1016/J.BBAPAP.2014.07.016
• [I] J KANG ET AL: "Rapid Formulation Development for Monoclonal Antibodies - BioProcess InternationalBioProcess International", 12 April 2016 (2016-04-12), XP055349129, Retrieved from the Internet <URL:http://www.bioprocessintl.com/manufacturing/formulation/rapid-formulation-development-for-monoclonal-antibodies/> [retrieved on 20170223]
• See also references of WO 2021023267A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
EP 4011390 A1 20220615; EP 4011390 A4 20230913; AU 2020325415 A1 20220224; BR 112022001775 A2 20220607; CA 3146138 A1 20210211; CN 114206382 A 20220318; CN 114206382 B 20240326; JP 2022543422 A 20221012; KR 20220044286 A 20220407; TW 202114639 A 20210416; TW I765311 B 20220521; US 2022281972 A1 20220908; WO 2021023267 A1 20210211

DOCDB simple family (application)
EP 20849224 A 20200806; AU 2020325415 A 20200806; BR 112022001775 A 20200806; CA 3146138 A 20200806; CN 2020107441 W 20200806; CN 202080055615 A 20200806; JP 2022506961 A 20200806; KR 20227004778 A 20200806; TW 109126706 A 20200806; US 202017631641 A 20200806